Drug Trial Radar · NCT06881264
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
401
Actual
Start
Apr 30, 2024
Primary completion
Sep 19, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
Conditions
- Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
Interventions
HR17031 injectionDrug
HR17031 injection
insulin glargineDrug
insulin glargine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c: Changes in HbA1c from baseline to week 26Time frame: week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.